Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SL-401 in Patients With Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

Trial Profile

SL-401 in Patients With Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tagraxofusp (Primary)
  • Indications Chronic myelomonocytic leukaemia; Hypereosinophilic syndrome; Myelofibrosis; Myeloproliferative disorders; Systemic mastocytosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 08 Jul 2019 According to a Stemline Therapeutics media release, the company expect to open enrollment of the new cohort in 4Q19.
    • 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2019 Results (n=23) of relapsed/refractory myelofibrosis patients presented at the 55th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top